Lilly’s $780M Bet is Reshaping Surgical Infection Prevention, and PolyPid’s Asset is Hiding in Plain Sight

PolyPid Sets July 15, 2026 Shareholder Meeting to Vote on Board, Auditor and Equity Grants

PolyPid announces shareholder meeting notice

PolyPid submits D-PLEX100 NDA to FDA under rolling review

PolyPid - FDA Decision on D-Plex100 Expected in Q1 2027 Under Pdufa Timeline

PolyPid Completes New Drug Application Submission to FDA for D-Plex₁₀₀

PolyPid management attends Craig-Hallum institutional investor conference investor meetings

PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference

PolyPid’s Earnings Call Signals Tightrope to Approval

PolyPid reports Q1 EPS (35c), consensus (43c)

PolyPid Ltd reports results for the quarter ended December 31 - Earnings Summary

PolyPid Advances D-PLEX₁₀₀ Toward FDA Review as Q1 2026 Loss Narrows and Debt Is Retired

PolyPid Q1 FY26 net loss narrows 7.61% to $7.7 million

PolyPid Q1 EPS $(0.35) Beats $(0.43) Estimate

PolyPid Ltd - U.S. Commercial Partnership Discussions for D-Plex100 in Late Stages

Press Release: PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results

Calendar of U.S. Earnings Expected in the Week Ahead

PolyPid Ltd expected to post a loss of 43 cents a share - Earnings Preview

PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026

PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting